Graf M, Krüssel J S, Conrad M, Bielfeld P, Rudolf K
Institut für Hormon- und Fortpflanzungsforschung an der Universität Hamburg.
Geburtshilfe Frauenheilkd. 1995 Jul;55(7):387-92. doi: 10.1055/s-2007-1022807.
To investigate the need for hormonal treatment in patients with functional ovarian cysts (FOC), the efficacy of this treatment was evaluated in a retrospective and also in a randomised prospective study. By retrospective analyses the resolution of FOC with a mean diameter larger than 2.0 cm at the beginning of a cycle was determined in 113 patients (31.6 +/- 4.6 years). Fifty-seven women received an oral contraceptive (ethinylestradiol 50 micrograms/d for 7 days, ethinylestradiol 50 micrograms and desogestrel 125 micrograms/d for 15 days), the others had no therapy. In a second study 59 patients (32.3 +/- 4.6 years) were randomised to receive a combination of ethinylestradiol 50 micrograms and levonorgestrel 250 micrograms/d for 21 days (Group 1, n = 24), or lynestrenol 10 mg/d continuously (Group 2, n = 14) or a third group (Group 3, n = 21) without treatment. In both studies no differences were found between those patients who had hormonal treatment and those who had not. The prospective study revealed that spontaneously appearing FOC and FOC evolving after ovulation induction during the cycle prior to study enrolment, resolved equally well within 12 weeks independent of contraceptive or gestagen treatment. FOC persisted in only one woman (group 2) who had a surgically proven endometrioma. In conclusion, hormonal treatment does not produce regression of FOC in women of reproductive age.
为了研究功能性卵巢囊肿(FOC)患者对激素治疗的需求,在一项回顾性研究和一项随机前瞻性研究中评估了这种治疗的疗效。通过回顾性分析,确定了113例患者(年龄31.6±4.6岁)在一个周期开始时平均直径大于2.0 cm的FOC的消退情况。57名女性接受了口服避孕药(炔雌醇50微克/天,共7天;炔雌醇50微克和去氧孕烯125微克/天,共15天),其他患者未接受治疗。在第二项研究中,59例患者(年龄32.3±4.6岁)被随机分组,分别接受炔雌醇50微克和左炔诺孕酮250微克/天的联合用药,共21天(第1组,n = 24),或炔诺酮10毫克/天持续用药(第2组,n = 14),或第三组(第3组,n = 21)不接受治疗。在两项研究中,接受激素治疗的患者与未接受治疗的患者之间均未发现差异。前瞻性研究表明,在入组研究前的周期中自发出现的FOC以及排卵诱导后出现的FOC,无论是否接受避孕药或孕激素治疗,在12周内消退情况相同。仅1名患有手术证实的子宫内膜瘤的女性(第2组)FOC持续存在。总之,激素治疗不会使育龄期女性的FOC消退。